This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


VBL Therapeutics

Drug Names(s): VB 201

Description: VB-201 [(R)-1-hexadecyl-2-(4-carboxy)butyl-sn-glycero-3-phosphocholine] is a phospholipid analog from the family of anti-inflammatory compounds developed by VBL called lecinoxoids. VB-201 targets the innate immune system through antagonism of Toll-Like Receptor (TLR)-2 and TLR-4 co-receptor, CD-14, and the inhibition of chemokine-mediated migration of monocytes to inflamed tissue.

VB-201 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug